Hester Biosciences Limited

Hester Biosciences Limited (HESTERBIO) is a micro-cap Healthcare company valued at ₹1,906 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Hester Biosciences Limited last traded at ₹2,236, modestly up 1.80% on the day.

Recent developments

On 2026-08-05, Hester Biosciences reported strong standalone growth in its June quarter results, with management highlighting expansion into pet care and poultry health products as key drivers for sustained growth.

Financial performance

The company's business has improved significantly, with annual net profit rising 98.2% to ₹57 crore, driven by a sharp increase in net profit margin to 17.3% from 9.3%. However, the latest quarter showed a drop in revenue of 8.0% compared to the same quarter a year earlier, while net profit surged 469.0% to ₹97 crore.

Valuation multiples

The stock trades at 33.1 times earnings, broadly in line with the Healthcare median of 32.0, 5.43 times book value. It yields 0.5%.

Things to watch

The stock is 16.7% below its 52-week high, and promoter holding fell by 9.45 percentage points in the latest quarter. The recent drop in quarterly revenue compared to the same quarter a year earlier could signal short-term challenges despite strong profit growth.

Where it stands

Hester Biosciences has seen a sharp rise in net profit, with the latest quarter showing a 469.0% increase to ₹97 crore, while annual net profit grew 98.2% to ₹57 crore. The stock remains 16.7% below its 52-week high, and promoter holding has declined in the quarter.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.